The fact that the FDA announced that it would not prepare a draft of the report for the menthol subcommittee demonstrates that when provided with overwhelmly convincing data and arguments , the FDA will modify its position.
It is for this reason that stakeholders must express their views on the five controlling issues which resulted from the first menthol subcommittee meeting and are delineated on this post http://www.thecre.com/tpsac/?p=561 .
It is imperative that stakeholders assist CRE in the construction of a “public docket” by providing relevant scientific and legal analysis on this forum at http://www.thecre.com/dqa/ which will provide the basis for demanding further modifications to TPSAC procedures.
Simply type your post and press “send”—no registration needed. The forum has the capability which allows you to submit documents.
N. B. CRE appreciates the public comments we received on the issue raised by GSK regarding smokeless tobacco at http://www.thecre.com/tpsac/?p=570